Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Moffitt Cancer Center Researchers Identify Genetic Variants for Prostate Cancers

Published: Monday, June 24, 2013
Last Updated: Monday, June 24, 2013
Bookmark and Share
Researchers have developed a method for identifying aggressive prostate cancers that require immediate therapy.

It relies on understanding the genetic interaction between single nucleotide polymorphisms (SNPs). The goal is to better predict a prostate cancer’s aggressiveness to avoid unnecessary radical treatment.

Their study was published in the online journal PLOS ONE in April.

According to the authors, prostate cancer accounts for 20 percent of all cancers and 9 percent of cancer deaths. It is the most common cancer and was the second leading cause of cancer death in American men in 2012.

“For most prostate cancer patients, the disease progresses relatively slowly,” said study co-author Hui-Yi Lin, Ph.D., assistant member of the Chemical Biology and Molecular Medicine Program at Moffitt. “However, some cases grow aggressively and metastasize. It is often difficult to tell the difference between the two.”

The two treatment options for aggressive prostate cancer — radical surgery and radiation therapy — have negative side effects, such as incontinence and erectile dysfunction. It is why the authors believe there is an urgent need for biomarkers that can identify or predict aggressive types of prostate cancer.

Through examining combinations of genetic variants, or SNP-SNP interactions, the researchers have identified and validated several genetic changes that are related to prostate cancer aggressiveness. Their work also shows that the epithelial growth factor receptor may be the hub for these interactions because it is involved in the growth of blood vessels (angiogenesis), which in turn stimulates tumor growth.

“Our findings identified five SNP-SNP interactions in the angiogenesis genes associated with prostate cancer aggressiveness,” explained study co-author Jong Y. Park, Ph.D., associate member of Moffitt’s Cancer Epidemiology Program. “We successfully detected the genotype combinations that put patients at risk of aggressive prostate cancer and then explored the underlying biological associations among angiogenesis genes associated with aggressive prostate cancer.”

The researchers concluded that the gene network they constructed based on SNP-SNP interactions indicates there are novel relationships among critical genes involved in the angiogenesis pathway in prostate cancer.

“Our findings will help physicians identify patients with an aggressive type of prostate cancer and may lead to better personalized treatment in the future,” Park said.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Moffitt, Vermillion Collaborate to Model Improvements in Ovarian Cancer Care
The purpose of the study is to produce clinical and economic data to support a new value-based practice model.
Monday, May 12, 2014
Protein Complex Linked to Cancer Growth May Also Help Fight Tumors
Researchers have discovered a gene expression signature that may lead to new immune therapies for lung cancer patients.
Thursday, July 25, 2013
Race, Ethnicity Affect Likelihood of Finding a Suitable Unrelated Stem Cell Donor
Researchers at Moffitt Cancer Center describe the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT).
Monday, September 17, 2012
Moffitt, Sanford-Burnham and Florida Hospital Create Personalized Medicine Partnership
The partnership will conduct collaborative research to accelerate discovery and to develop new treatments in the areas of cancer and metabolic diseases.
Thursday, February 16, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!